Cystic Fibrosis Lung Function Improved With Triple Therapy
Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and...
Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently...
#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Pha
Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency...
FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI
AzurRx BioPharma is planning a multi-center Phase 2 trial to be conducted in the United States and Europe to evaluate its lead candidate...
Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways
New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...
Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment
Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum...